Aytu BioScience, Inc. (AYTU): Price and Financial Metrics

Aytu BioScience, Inc. (AYTU): $2.26

0.03 (-1.31%)

POWR Rating

Component Grades








Add AYTU to Watchlist
Sign Up

Industry: Biotech




#47 of 342

in industry

AYTU Price/Volume Stats

Current price $2.26 52-week high $4.88
Prev. close $2.29 52-week low $1.38
Day low $2.26 Volume 214
Day high $2.26 Avg. volume 95,532
50-day MA $2.68 Dividend yield N/A
200-day MA $2.14 Market Cap 12.58M

AYTU Stock Price Chart Interactive Chart >


  • AYTU scores best on the Growth dimension, with a Growth rank ahead of 77.56% of US stocks.
  • The strongest trend for AYTU is in Sentiment, which has been heading up over the past 84 days.
  • AYTU's current lowest rank is in the Momentum metric (where it is better than 8.76% of US stocks).

AYTU Stock Summary

  • AYTU has a market capitalization of $16,092,379 -- more than approximately only 8.89% of US stocks.
  • AYTU's price/sales ratio is 0.15; that's higher than the P/S ratio of just 5.1% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AYTU comes in at -55.12% -- higher than that of merely 9.86% of stocks in our set.
  • Stocks that are quantitatively similar to AYTU, based on their financial statements, market capitalization, and price volatility, are TOMZ, ANGI, TREE, PRPH, and MITQ.
  • AYTU's SEC filings can be seen here. And to visit AYTU BIOPHARMA INC's official web site, go to aytubio.com.

AYTU Valuation Summary

  • In comparison to the median Healthcare stock, AYTU's price/earnings ratio is 103.7% lower, now standing at -0.9.
  • AYTU's price/earnings ratio has moved down 0.9 over the prior 105 months.

Below are key valuation metrics over time for AYTU.

Stock Date P/S P/B P/E EV/EBIT
AYTU 2023-11-03 0.1 0.4 -0.9 -0.6
AYTU 2023-11-02 0.1 0.4 -0.9 -0.5
AYTU 2023-11-01 0.1 0.4 -0.9 -0.5
AYTU 2023-10-31 0.1 0.4 -0.9 -0.5
AYTU 2023-10-30 0.1 0.4 -0.9 -0.5
AYTU 2023-10-27 0.1 0.4 -0.9 -0.5

AYTU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AYTU has a Quality Grade of D, ranking ahead of 15.62% of graded US stocks.
  • AYTU's asset turnover comes in at 0.311 -- ranking 147th of 682 Pharmaceutical Products stocks.
  • SYRS, ONVO, and GTHX are the stocks whose asset turnover ratios are most correlated with AYTU.

The table below shows AYTU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.311 0.445 -6.155
2021-03-31 0.311 0.508 -2.810
2020-12-31 0.334 0.683 -2.327
2020-09-30 0.301 0.723 -2.482
2020-06-30 0.265 0.727 -23.603
2020-03-31 0.194 0.749 8.971

AYTU Price Target

For more insight on analysts targets of AYTU, see our AYTU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.50 Average Broker Recommendation 1.5 (Moderate Buy)

Aytu BioScience, Inc. (AYTU) Company Bio

Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.

AYTU Latest News Stream

Event/Time News Detail
Loading, please wait...

AYTU Latest Social Stream

Loading social stream, please wait...

View Full AYTU Social Stream

Latest AYTU News From Around the Web

Below are the latest news stories about AYTU BIOPHARMA INC that investors may wish to consider to help them evaluate AYTU as an investment opportunity.

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript November 14, 2023 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.00148, expectations were $-0.04. Robert Blum: Good afternoon, everyone, and thank you for joining us for Aytu BioPharma’s Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining […]

Yahoo | November 15, 2023

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Q1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balance at September 30, 2023Company to host conference ...

Yahoo | November 14, 2023

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Ranked 118th Fastest Growing Company in North AmericaRanked 23rd Fastest Growing Life Sciences CompanyDENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing ...

Yahoo | November 8, 2023

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 ...

Yahoo | November 7, 2023

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report ...

Yahoo | October 26, 2023

Read More 'AYTU' Stories Here

AYTU Price Returns

1-mo -16.30%
3-mo 32.16%
6-mo 24.18%
1-year -46.90%
3-year -98.69%
5-year -98.88%
YTD -40.21%
2022 -86.00%
2021 -77.42%
2020 -38.51%
2019 23.10%
2018 -98.23%

Continue Researching AYTU

Here are a few links from around the web to help you further your research on Aytu Bioscience Inc's stock as an investment opportunity:

Aytu Bioscience Inc (AYTU) Stock Price | Nasdaq
Aytu Bioscience Inc (AYTU) Stock Quote, History and News - Yahoo Finance
Aytu Bioscience Inc (AYTU) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!